Avivo was one of five companies selected for funding under the Government of Canada’s Life Sciences Fund to advance dual-use innovations and strengthen Canada’s industrial capacity.
Catégorie : Communauté
GlycoNet Investigators inducted into the Royal Society of Canada
Congratulations to Drs. Jason Acker and Lara Mahal on receiving Canada’s highest academic honour.
Coup d’œil sur la science des sucres : faits saillants du Symposium Canadien sur la Glycomique 2026
Over 190 researchers, industry experts, and emerging talent in glycomics gathered for the 9th Canadian Glycomics Symposium, in Canmore, Alberta, May 12-14, 2026.
Could seaweed support healthier herds?
New research from the lab of GlycoNet investigator Wade Abbot finds cows have gut microbes that enable them to digest the sugars in seaweed.
GlycoNet-Supported Startup Synakis Announces Close of Oversubscribed Pre-Seed Round
The CAD $2.6 million pre-seed financing round included support from GlycoNet’s Kickstart Program.
Sussex Research and GlycoNet-Supported Startup 48Hour Discovery Announce Strategic Partnership
Together, they will develop and commercialize game-changing Liquid Glycan Array (LiGA) reagents designed to enable high-throughput, multiplex profiling of protein-glycan interactions on cell surfaces.
From blood innovation to biodefence: Next-generation health solutions for soldiers and civilians
Dr. Warren Wakarchuk highlights how glycomics research supports national security on multiple fronts.
Le rôle des sucres dans l’avenir de la médecine et de l’agriculture
This article highlights some of the ways that Canadian researchers are using glycomics to drive medical breakthroughs and more sustainable
32nd International Carbohydrate Symposium
GlycoNet will be attending the 32nd International Carbohydrate Symposium (ICS 2026), taking place July 5–9, 2026, in Bratislava, Slovakia.
AdvanCell and GlycoNet-supported startup 48Hour Discovery announce collaboration and exclusive licensing agreement
48Hour Discovery partners with AdvanCell to advance a peptide-based Lead-212 radioligand therapy program for oncology.